Levofloxacin

Background ,[object Object],[object Object],[object Object],[object Object],[object Object]

Racemic mixtures ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Chirality ,[object Object],[object Object],[object Object],[object Object]

Advantages of chirality ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Levofloxacin Viewing the Benefits & Add-vantages

Mechanism of action ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Absorption ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Distribution ,[object Object],[object Object],[object Object],[object Object],[object Object]

Sequential therapy IV Vs. Oral Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections By Mario Furlanut et al, Journal of Antimicrobial Chemotherapy (2003) 51, 101–106.

Coverage of Main RTI Pathogens ,[object Object]

Comparative therapy in RTI ,[object Object],[object Object],[object Object],[object Object],Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae by Mark W. Garrison et al, Journal of Antimicrobial Chemotherapy (2003) 52, 503–506.

Levofloxacin = higher urine levels Levofloxacin demonstrated rapid bactericidal activity against E coli in the urine (with MICs ≤32 µg/mL at 1.5 hr).

Lesser resistance with just 5 days of therapy

Significantly lower resistance rates ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Significantly high success in prostatitis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Activity in complicated SSTI ,[object Object],Once-Daily, High-Dose Levofloxacin versus Ticarcillin-Clavulanate alone or followed by Amoxicillin-Clavulanate for complicated Skin and Skin-Structure Infections: A Randomized, Open-Label Trial by Donald R. Graham et al, Clinical Infectious Diseases 2002;35:381–389

Activity in diabetic foot infections ,[object Object],[object Object],Tissue and serum levofloxacin concentrations in diabetic foot infection patients by K. Oberdorfer et al, Journal of Antimicrobial Chemotherapy (2004) 54, 836-839.

Activity in bone ,[object Object],[object Object],Diffusion of levofloxacin into bone and synovial tissues by T. Rimmelé et al, Journal of Antimicrobial Chemotherapy (2004) 53, 533-535.

Better activity in combination ,[object Object],[object Object]

Typhoid and levofloxacin ,[object Object]

Guidelines, and Recommendations ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Indications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Side effects and ADRs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Dosing ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Summary Levoz Lower MICs Guideline recommended antibacterial One a day antibacterial for a wide variety of indications 5 days therapy in URTI Higher urine levels for better UTI activity / ↓ in PSA in ch. prostatitis Excellent success in resistant typhoid Sequential therapy / combination therapy Excellent tolerability

Levofloxacin

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Semelhante a Levofloxacin

Semelhante a Levofloxacin (20)

Mais de BALASUBRAMANIAM IYER

Mais de BALASUBRAMANIAM IYER (20)

Último

Último (20)

Levofloxacin